Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02925221Completed

Canadian Medical Assessment of JINARC™ Outcomes Registry

Role: lead

NCT04830215Phase 4Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Role: collaborator

NCT04907279Unknown

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

Role: lead

NCT03585127Not ApplicableCompleted

Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia

Role: collaborator

All 4 trials loaded